Biomarkers in Neurocritical Care

Neurotherapeutics

Volumn 9, Issue 1, 2012, Pages 17-23

  Kimberly, W Taylor ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Biomarker; Intracranial monitor; Neurocritical care; Neuroimaging; Surrogate endpoint

Indexed keywords

BIOLOGICAL MARKER;

HUMAN; INTENSIVE CARE; NEUROCRITICAL CARE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

BIOLOGICAL MARKERS; BRAIN DISEASES; CRITICAL CARE; HUMANS; NEUROIMAGING; PROGNOSIS;

EID: 84856570611     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-011-0089-2     Document Type: Review

References (79)

1. Atkinson AJ, Colburn WA, DeGruttola VG, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
2. Vespa P. What is the optimal threshold for cerebral perfusion pressure following traumatic brain injury? Neurosurg Focus 2003; 15: E4.
3. Cunningham AS, Salvador R, Coles JP, et al. Physiological thresholds for irreversible tissue damage in contusional regions following traumatic brain injury. Brain 2005; 128: 1931-1942.
4. Robertson CS, Valadka AB, Hannay HJ, et al. Prevention of secondary ischemic insults after severe head injury. Crit Care Med 1999; 27: 2086-2095.
5. Rosner MJ, Rosner SD, Johnson AH. Cerebral perfusion pressure: management protocol and clinical results. J Neurosurg 1995; 83: 949-962.
6. Gopinath SP, Robertson CS, Contant CF, et al. Jugular venous desaturation and outcome after head injury. J Neurol Neurosurg Psychiatry 1994; 57: 717-723.
7. Muizelaar JP, Marmarou A, Ward JD, et al. Adverse effects of prolonged hyperventilation in patients with severe head injury: a randomized clinical trial. J Neurosurg 1991; 75: 731-739.
8. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The proact II study: a randomized controlled trial. Prolyse in acute cerebral thromboembolism. JAMA 1999; 282: 2003-2011.
9. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-1587.
10. Graham GD. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke 2003; 34: 2847-2850.
11. Kimberly WT, Sheth KN. Approach to severe hemispheric stroke. Neurology 2011; 76: S50-S56.
12. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017-1025.
13. Molina CA, Alvarez-Sabin J, Montaner J, et al. Thrombolysis-related hemorrhagic infarction: a marker of early reperfusion, reduced infarct size, and improved outcome in patients with proximal middle cerebral artery occlusion. Stroke 2002; 33: 1551-1556.
14. Fiehler J, Remmele C, Kucinski T, et al. Reperfusion after severe local perfusion deficit precedes hemorrhagic transformation: an MRI study in acute stroke patients. Cerebrovasc Dis 2005; 19: 117-124.
15. Berger C, Fiorelli M, Steiner T, et al. Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic? Stroke 2001; 32: 1330-1335.
16. Larrue V, von Kummer RR, Muller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001; 32: 438-441.
17. Thomalla G, Sobesky J, Kohrmann M, et al. Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia: MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours. Stroke 2007; 38: 313-318.
18. Sumii T, Lo EH. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 2002; 33: 831-836.
19. Wang X, Tsuji K, Lee SR, et al. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 2004; 35: 2726-2730.
20. Ning M, Furie KL, Koroshetz WJ, et al. Association between tpa therapy and raised early matrix metalloproteinase-9 in acute stroke. Neurology 2006; 66: 1550-1555.
21. Castellanos M, Sobrino T, Millan M, et al. Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study. Stroke 2007; 38: 1855-1859.
22. Montaner J, Molina CA, Monasterio J, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003; 107: 598-603.
23. Vahedi K, Hofmeijer J, Juettler E, et al. Early decompressive surgery in malignant infarction of the middle cerebral artery: A pooled analysis of three randomised controlled trials. Lancet Neurol 2007; 6: 215-222.
24. Kasner SE, Demchuk AM, Berrouschot J, et al. Predictors of fatal brain edema in massive hemispheric ischemic stroke. Stroke 2001; 32: 2117-2123.
25. Pullicino PM, Alexandrov AV, Shelton JA, Alexandrova NA, Smurawska LT, Norris JW. Mass effect and death from severe acute stroke. Neurology 1997; 49: 1090-1095.
26. Bloomfield SM, McKinney J, Smith L, Brisman J. Reliability of s100b in predicting severity of central nervous system injury. Neurocrit Care 2007; 6: 121-138.
27. Foerch C, Otto B, Singer OC, et al. Serum s100b predicts a malignant course of infarction in patients with acute middle cerebral artery occlusion. Stroke 2004; 35: 2160-2164.
28. Castellanos M, Leira R, Serena J, et al. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke 2004; 35: 1671-1676.
29. Serena J, Blanco M, Castellanos M, et al. The prediction of malignant cerebral infarction by molecular brain barrier disruption markers. Stroke 2005; 36: 1921-1926.
30. Qureshi AI, Mendelow AD, Hanley DF. Intracerebral haemorrhage. Lancet 2009; 373: 1632-1644.
31. Brott T, Broderick J, Kothari R, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 1997; 28: 1-5.
32. Flibotte JJ, Hagan N, O'Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 2004; 63: 1059-1064.
33. Davis SM, Broderick J, Hennerici M, et al. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology 2006; 66: 1175-1181.
34. Mayer SA, Brun NC, Begtrup K, et al. Efficacy and safety of recombinant activated factor vii for acute intracerebral hemorrhage. N Engl J Med 2008; 358: 2127-2137.
35. Wada R, Aviv RI, Fox AJ, et al. Ct angiography "spot sign" predicts hematoma expansion in acute intracerebral hemorrhage. Stroke 2007; 38: 1257-1262.
36. Becker KJ, Baxter AB, Bybee HM, Tirschwell DL, Abouelsaad T, Cohen WA. Extravasation of radiographic contrast is an independent predictor of death in primary intracerebral hemorrhage. Stroke 1999; 30: 2025-2032.
37. Saatman KE, Duhaime AC, Bullock R, Maas AI, Valadka A, Manley GT. Classification of traumatic brain injury for targeted therapies. J Neurotrauma 2008; 25: 719-738.
38. Becker DP, Miller JD, Ward JD, Greenberg RP, Young HF, Sakalas R. The outcome from severe head injury with early diagnosis and intensive management. J Neurosurg 1977; 47: 491-502.
39. Lundberg N, Troupp H, Lorin H. Continuous recording of the ventricular-fluid pressure in patients with severe acute traumatic brain injury. A preliminary report. J Neurosurg 1965; 22: 581-590.
40. Narayan RK, Greenberg RP, Miller JD, et al. Improved confidence of outcome prediction in severe head injury. A comparative analysis of the clinical examination, multimodality evoked potentials, CT scanning, and intracranial pressure. J Neurosurg 1981; 54: 751-762.
41. Narayan RK, Kishore PR, Becker DP, et al. Intracranial pressure: to monitor or not to monitor? A review of our experience with severe head injury. J Neurosurg 1982; 56: 650-659.
42. Palmer S, Bader MK, Qureshi A, et al. The impact on outcomes in a community hospital setting of using the aans traumatic brain injury guidelines. American Association for Neurologic Surgeons. J Trauma 2001; 50: 657-664.
43. Fakhry SM, Trask AL, Waller MA, Watts DD. Management of brain-injured patients by an evidence-based medicine protocol improves outcomes and decreases hospital charges. J Trauma 2004; 56: 492-500.
44. Eisenberg HM, Frankowski RF, Contant CF, Marshall LF, Walker MD. High-dose barbiturate control of elevated intracranial pressure in patients with severe head injury. J Neurosurg 1988; 69: 15-23.
45. Saul TG, Ducker TB. Effect of intracranial pressure monitoring and aggressive treatment on mortality in severe head injury. J Neurosurg 1982; 56: 498-503.
46. Bratton SL, Chestnut RM, Ghajar J, et al. Guidelines for the management of severe traumatic brain injury. Ix. Cerebral perfusion thresholds. J Neurotrauma 2007; 24(suppl 1): S59-S64.
47. Bratton SL, Chestnut RM, Ghajar J, et al. Guidelines for the management of severe traumatic brain injury. Viii. Intracranial pressure thresholds. J Neurotrauma 2007; 24(suppl 1): S55-S58.
48. Robertson CS, Gopinath SP, Goodman JC, Contant CF, Valadka AB, Narayan RK. Sjvo2 monitoring in head-injured patients. J Neurotrauma 1995; 12: 891-896.
49. Stiefel MF, Spiotta A, Gracias VH, et al. Reduced mortality rate in patients with severe traumatic brain injury treated with brain tissue oxygen monitoring. J Neurosurg 2005; 103: 805-811.
50. Valadka AB, Gopinath SP, Contant CF, Uzura M, Robertson CS. Relationship of brain tissue PO2 to outcome after severe head injury. Crit Care Med 1998; 26: 1576-1581.
51. Cruz J. The first decade of continuous monitoring of jugular bulb oxyhemoglobinsaturation: management strategies and clinical outcome. Crit Care Med 1998; 26: 344-351.
52. Tisdall MM, Smith M. Cerebral microdialysis: research technique or clinical tool. Br J Anaesth 2006; 97: 18-25.
53. Belli A, Sen J, Petzold A, Russo S, Kitchen N, Smith M. Metabolic failure precedes intracranial pressure rises in traumatic brain injury: a microdialysis study. Acta Neurochir (Wien) 2008; 150: 461-470.
54. Timofeev I, Carpenter KL, Nortje J, et al. Cerebral extracellular chemistry and outcome following traumatic brain injury: a microdialysis study of 223 patients. Brain 2011; 134: 484-494.
55. Signorini DF, Andrews PJ, Jones PA, Wardlaw JM, Miller JD. Predicting survival using simple clinical variables: A case study in traumatic brain injury. J Neurol Neurosurg Psychiatry 1999; 66: 20-25.
56. Eisenberg HM, Gary HE Jr, Aldrich EF, et al. Initial ct findings in 753 patients with severe head injury. A report from the nih traumatic coma data bank. J Neurosurg 1990; 73: 688-698.
57. Wardlaw JM, Easton VJ, Statham P. Which ct features help predict outcome after head injury? J Neurol Neurosurg Psychiatry 2002; 72: 188-192.
58. Marquez de la Plata C, Ardelean A, Koovakkattu D, et al. Magnetic resonance imaging of diffuse axonal injury: quantitative assessment of white matter lesion volume. J Neurotrauma 2007; 24: 591-598.
59. Babikian T, Freier MC, Tong KA, et al. Susceptibility weighted imaging: Neuropsychologic outcome and pediatric head injury. Pediatr Neurol 2005; 33: 184-194.
60. Shutter L, Tong KA, Holshouser BA. Proton mrs in acute traumatic brain injury: role for glutamate/glutamine and choline for outcome prediction. J Neurotrauma 2004; 21: 1693-1705.
61. Warner MA, Marquez de la Plata C, Spence J, et al. Assessing spatial relationships between axonal integrity, regional brain volumes, and neuropsychological outcomes after traumatic axonal injury. J Neurotrauma 2010; 27: 2121-2130.
62. Petzold A, Green AJ, Keir G, et al. Role of serum s100b as an early predictor of high intracranial pressure and mortality in brain injury: a pilot study. Crit Care Med 2002; 30: 2705-2710.
63. Vos PE, Lamers KJ, Hendriks JC, et al. Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Neurology 2004; 62: 1303-1310.
64. Raabe A, Grolms C, Keller M, Dohnert J, Sorge O, Seifert V. Correlation of computed tomography findings and serum brain damage markers following severe head injury. Acta Neurochir (Wien) 1998; 140: 787-791.
65. Mondello S, Papa L, Buki A, et al. Neuronal and glial markers are differently associated with computed tomography findings and outcome in patients with severe traumatic brain injury: a case control study. Crit Care 2011; 15: R156.
66. Pierot L, Aggour M, Moret J. Vasospasm after aneurysmal subarachnoid hemorrhage: recent advances in endovascular management. Curr Opin Crit Care 2010; 16: 110-116.
67. Longstreth WT Jr., Nelson LM, Koepsell TD, van Belle G. Clinical course of spontaneous subarachnoid hemorrhage: a population-based study in king county, washington. Neurology 1993; 43: 712-718.
68. Macdonald RL, Pluta RM, Zhang JH. Cerebral vasospasm after subarachnoid hemorrhage: the emerging revolution. Nat Clin Pract Neurol 2007; 3: 256-263.
69. Rabinstein AA, Weigand S, Atkinson JL, Wijdicks EF. Patterns of cerebral infarction in aneurysmal subarachnoid hemorrhage. Stroke 2005; 36: 992-997.
70. Schmidt JM, Wartenberg KE, Fernandez A, et al. Frequency and clinical impact of asymptomatic cerebral infarction due to vasospasm after subarachnoid hemorrhage. J Neurosurg 2008; 109: 1052-1059.
71. Shimoda M, Takeuchi M, Tominaga J, Oda S, Kumasaka A, Tsugane R. Asymptomatic versus symptomatic infarcts from vasospasm in patients with subarachnoid hemorrhage: serial magnetic resonance imaging. Neurosurgery 2001; 49: 1341-1350.
72. Vergouwen MD, Etminan N, Ilodigwe D, Macdonald RL. Lower incidence of cerebral infarction correlates with improved functional outcome after aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab 2011; 31: 1545-1553.
73. Kreiter KT, Mayer SA, Howard G, et al. Sample size estimates for clinical trials of vasospasm in subarachnoid hemorrhage. Stroke 2009; 40: 2362-2367.
74. Yoon DY, Choi CS, Kim KH, Cho BM. Multidetector-row ct angiography of cerebral vasospasm after aneurysmal subarachnoid hemorrhage: comparison of volume-rendered images and digital subtraction angiography. AJNR Am J Neuroradiol 2006; 27: 370-377.
75. Chaudhary SR, Ko N, Dillon WP, et al. Prospective evaluation of multidetector-row ct angiography for the diagnosis of vasospasm following subarachnoid hemorrhage: a comparison with digital subtraction angiography. Cerebrovasc Dis 2008; 25: 144-150.
76. Lysakowski C, Walder B, Costanza MC, Tramer MR. Transcranial doppler versus angiography in patients with vasospasm due to a ruptured cerebral aneurysm: a systematic review. Stroke 2001; 32: 2292-2298.
77. Claassen J, Mayer SA, Hirsch LJ. Continuous eeg monitoring in patients with subarachnoid hemorrhage. J Clin Neurophysiol 2005; 22: 92-98.
78. Jaeger M, Schuhmann MU, Soehle M, Nagel C, Meixensberger J. Continuous monitoring of cerebrovascular autoregulation after subarachnoid hemorrhage by brain tissue oxygen pressure reactivity and its relation to delayed cerebral infarction. Stroke 2007; 38: 981-986.
79. Unterberg AW, Sakowitz OW, Sarrafzadeh AS, Benndorf G, Lanksch WR. Role of bedside microdialysis in the diagnosis of cerebral vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurg 2001; 94: 740-749.